# The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring

> **NCT03790631** · — · COMPLETED · sponsor: **University of Geneva, Switzerland** · enrollment: 771 (actual)

## Conditions studied

- Beta-lactam Antibiotics
- Therapeutic Drug Monitoring
- Toxicity
- Efficacy
- Imipenem
- Meropenem
- Piperacillin
- Flucloxacillin
- Amoxicillin
- Ceftazidime
- Cefepime

## Interventions

- **OTHER:** The study is observational.

## Key facts

- **NCT ID:** NCT03790631
- **Lead sponsor:** University of Geneva, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 771 (ACTUAL)
- **Last updated:** 2025-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790631, "The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03790631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*